Laboratorios Rovi will manufacture the active ingredient of Moderna’s vaccine in Granada


Madrid

Updated:

Keep

Rovi Pharmaceutical Laboratories will manufacture Moderna’s vaccine in Spain. Today it has announced that it will manufacture the active ingredient of Moderna’s vaccine at its facilities in Granada, while the subsequent process of
filling and finishing
He has been doing it in Madrid for months.

In this way, the pharmaceutical reinforces their collaboration with Moderna and will carry out a new industrial investment in the facilities it has in the Andalusian city. This investment consists of the installation of a new support line for the production phases of the active ingredient of the mRNA vaccine, which are prior to and additional to the formulation, filling and finishing of the same, as the company has informed the National Securities Market Commission (CNMV).

This line would have a production capacity equivalent to more than 100 million doses per year. According to the statement issued by Rovi, it is expected to start supplying markets outside the United States in the third quarter of 2021. Following this announcement, Rovi’s shares have risen more than 4% on the stock market, exceeding 48 euros per share. .

With this action, Rovi expands the activities it carries out in the Moderna vaccine manufacturing process: it will participate in the manufacture of the active ingredient as well as in its formulation, packaging and final packaging, prior to distribution for administration to patients.

“We are very happy for the collaboration with Moderna, whose vaccine against Covid-19 is one of the best positioned in the race to solve this health crisis. We are extremely excited that Rovi is going one step further and participating in the manufacture of the active ingredient in the vaccine, since greater integration in the production process would allow us to support Moderna in its large-scale supply more widely ”, highlighted the counselor. Rovi delegate, Juan López-Belmonte Encina.

“Our proven experience and capabilities as a manufacturer of injectables for third parties of high technological value have allowed us to reinforce the current agreement with Moderna, which would contribute to the strengthening of our manufacturing area, predictably providing us with an opportunity for significant growth in this area”, has added.

See them
comments

.



Source link